LYMPHOPROLIFERATIVE DISORDER INVOLVING THE CERVIX IN A PATIENT BEING TREATED WITH FK-506

FK-506 is an immunosuppressive agent used mainly to prevent allograft rejection in organ transplant patients. Recently, it has been applied as a treatment for patients with autoimmune disorders. An entity calle d posttransplant lymphoproliferative disorder (PTLD) is a well-recogni zed result of immunosuppression in transplant patients receiving long- term immunosuppression. This disorder is a complication of treatment w ith FK-506 in 0.7 to 1.6% of transplant patients and is usually of B-c ell origin. A majority of patients have serologic evidence of EBV infe ction. We report a case of a patient receiving long-term FK-506 therap y for multiple sclerosis who developed lymphoproliferative disorder in volving the cervix. We will discuss the possible role of FK-506 initia tion of this tumor. (C) 1996 Academic Press, Inc.